Clinical Trial Update: Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder [Phase 2]

View source ↗

Summary

Amgen is conducting a Phase 2 pediatric trial of Inebilizumab for Neuromyelitis Optica Spectrum Disorder. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Uplizna (inebilizumab)

Snippet

Sponsor: Amgen | Conditions: Neuromyelitis Optica Spectrum Disorder | Phase 2 | Status: RECRUITING